Safety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, in patients with advanced malignancies.
N. Houede
No relevant relationships to disclose
S. J. Faivre
Consultant or Advisory Role - Amgen
Honoraria - Bayer; Merck Serono; Pfizer
A. Awada
No relevant relationships to disclose
E. Raymond
Consultant or Advisory Role - Bayer; Novartis; Pfizer
Honoraria - Bayer; Novartis; Pfizer
A. Italiano
No relevant relationships to disclose
T. Besse-Hammer
No relevant relationships to disclose
M. Donica
Employment or Leadership Position - Merck Serono
N. Rejeb
Employment or Leadership Position - Merck Serono
C. Luepfert
Employment or Leadership Position - Merck KGaA
S. Ongarello
Employment or Leadership Position - Merck Serono
Research Funding - Merck Serono
J. Delord
Expert Testimony - Roche